Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study)

Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study)

Casein glycomacropeptide (CGMP) has anti-inflammatory properties in experimental rodent colitis and using human in vitro inflammation models. Its use as a food ingredient has proven safe and with no influence on dietary intake. We hypothesize that orally administered CGMP has a beneficial effect comparable to that of mesalazine in active distal ulcerative colitis.

GCMP has mainly been used as food additive in patients with specific dietary needs, i.e. in infant formulas, adipositas, or in patient with phenylketonuria. Due to its antiinflammatory properties we hypothesize that it may be used alone or along with conventional therapy in inflammatory diseases such as ulcerative colitis.

Inclusion Criteria:

• Age 18 years or more
• Diagnosed ulcerative colitis
• Signs of clinical activity with SCCAI of 3 or more
• Extension more than 10 cm and no more than 40 cm from anus

Exclusion Criteria:

• Rectal temperature more than 38 degrees Celcius
• Diagnosed celiac disease or lactose intolerance
• Unable to speak or understand Danish
• Prior biologics or systemic steroids 4 weeks up to inclusion